We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

186 hedge funds and large institutions have $1.45B invested in Ocular Therapeutix in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more call options, than puts

Call options by funds: $9.7M | Put options by funds: $4.1M

56% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 48

44% more capital invested

Capital invested by funds: $1.01B → $1.45B (+$447M)

12.21% more ownership

Funds ownership: 86.38% → 98.59% (+12%)

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

5% less funds holding

Funds holding: 196 → 186 (-10)

23% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 31

Holders
186
Holders Change
-10
Holders Change %
-5.1%
% of All Funds
2.45%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
24
Increased
75
Reduced
48
Closed
31
Calls
$9.7M
Puts
$4.1M
Net Calls
+$5.6M
Net Calls Change
+$2.62M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$146M
2
PBA
Paradigm Biocapital Advisors
New York
+$16.5M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$10.6M
4
Invesco
Invesco
Georgia
+$5.75M
5
UBS Group
UBS Group
Switzerland
+$4.93M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$11.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10.3M
3
PA
Perceptive Advisors
New York
-$6.71M
4
ACA
Avoro Capital Advisors
New York
-$5.17M
5
SCM
Silverarc Capital Management
Massachusetts
-$4.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
51
VOYA Investment Management
Georgia
$2.71M -$352K -44,946 -13%
Macquarie Group
52
Macquarie Group
Australia
$2.25M -$23.1K -2,945 -1%
Deutsche Bank
53
Deutsche Bank
Germany
$2.23M -$142K -18,204 -7%
EAM
54
Erste Asset Management
Austria
$2.17M – – –
Ameriprise
55
Ameriprise
Minnesota
$2.16M +$1.29M +164,741 +242%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$2.09M +$19K +2,433 +1%
Balyasny Asset Management
57
Balyasny Asset Management
Illinois
$2.03M +$1.11M +142,424 +188%
UOC
58
UBS O'Connor
Illinois
$1.95M -$377K -48,158 -19%
BNP Paribas Financial Markets
59
BNP Paribas Financial Markets
France
$1.94M +$1.21M +154,047 +283%
IMC Chicago
60
IMC Chicago
Illinois
$1.93M +$1.63M +207,765 New
KCM
61
Knoll Capital Management
Florida
$1.86M – – –
Swiss National Bank
62
Swiss National Bank
Switzerland
$1.83M +$105K +13,400 +7%
Assenagon Asset Management
63
Assenagon Asset Management
Luxembourg
$1.8M -$1.16M -148,100 -43%
WAM
64
Weiss Asset Management
Massachusetts
$1.74M +$1.47M +187,615 New
RA
65
RoundAngle Advisors
New Jersey
$1.72M -$79.6K -10,169 -5%
BS
66
Banco Santander
Spain
$1.71M – – –
AllianceBernstein
67
AllianceBernstein
Tennessee
$1.51M – – –
DFCM
68
Dark Forest Capital Management
Puerto Rico
$1.5M +$1.27M +161,903 New
CC
69
Courier Capital
New York
$1.43M – – –
SEI Investments
70
SEI Investments
Pennsylvania
$1.43M +$73K +9,321 +6%
Verition Fund Management
71
Verition Fund Management
Connecticut
$1.38M +$612K +78,172 +111%
State of Wisconsin Investment Board
72
State of Wisconsin Investment Board
Wisconsin
$1.18M -$566K -72,349 -36%
T. Rowe Price Associates
73
T. Rowe Price Associates
Maryland
$1.17M +$4.89K +625 +0.5%
Millennium Management
74
Millennium Management
New York
$1.11M +$933K +119,146 New
LCM
75
Legato Capital Management
California
$1.05M -$2.11K -270 -0.2%
1 2
3
4 5

OCUL Hedge Fund Activity: Q2 2025 in Review

186 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2025, worth a combined $1.45B — up 44% from $1.01B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of OCUL and 24 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 75 added.

The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was BlackRock, cutting an estimated $11.5M.

  • 186 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2025, down from 196 in Q1 2025.
  • Funds reported $1.45B of Ocular Therapeutix stock for Q2 2025, up 44% quarter-over-quarter.
  • 24 funds opened new Ocular Therapeutix positions in Q2 2025 and 31 closed out, a net change of -7 holders.
  • The largest Ocular Therapeutix buyer in Q2 2025 was Fidelity Investments, an estimated $146M added.
  • The largest Ocular Therapeutix seller in Q2 2025 was BlackRock, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2025.